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ABSTRACT 
Background: Bacterial meningitis is responsible for 
significant morbidity and mortality, but early appropriate 
therapy is expected to improve outcomes. National treatment 
guidelines were published in 2004, but no assessment of their 
utilization in the U.S. has been reported. 
Objectives: To measure adherence to meningitis 
treatment guidelines and describe patient outcomes in relation to 
recommended antibiotic and dexamethasone use. 
Methods: Retrospective chart reviews were performed on 
patients with bacterial meningitis who presented to emergency 
departments at two community teaching hospitals. Timing 
and appropriateness of antibiotic and dexamethasone use 
were assessed according to national guidelines. Patient out-
comes of mortality, length of hospitalization, and neurological 
complications were analyzed based on therapies received.
Results: A total of 161 cases were identified; 38 met inclusion 
criteria. Recommended antibiotic regimens were administered 
to 52.6% of patients, while 26.3% received that regimen within 
eight hours. Dexamethasone was used in 44.7% of patients, but 
was administered prior to antibiotics in only 10.5% of cases. 
Mortality was numerically lower with recommended antibiotic 
therapy but did not reach statistical significance (5.0% versus 
16.7%; P = 0.33). Median length of stay was eight days for 
patients who received recommended antibiotics and 11 days 
for those who did not (P = 0.69). One patient who received 
dexamethasone had a neurological complication at discharge 
compared with four patients not receiving dexamethasone 
(5.9% versus 19.0%, P = 0.35).
Conclusion: Current treatment guidelines provide clinicians 
with direction on optimal care for patients with bacterial men-
ingitis, and an opportunity exists to improve implementation of 
these recommendations, which could improve patient outcomes. 
Keywords: bacterial meningitis, antibiotic therapy, 
dexamethasone, community-acquired disease
INTRODUCTION
Bacterial meningitis remains a very lethal disease, accounting 
for more than 4,000 cases and 500 deaths annually in the United 
States.1 The rate of occurrence has drastically decreased over 
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the past few decades, due largely to the increased vaccination 
against common pathogens. A 31% reduction in incidence of 
bacterial meningitis was seen from 1998–1999 to 2006–2007; 
however, fatality rates remain high for the cases of bacterial 
meningitis that do occur, with an overall mortality rate of 14.3%.1
No prospective studies exist regarding the relationship of 
antibiotic timing with clinical outcomes in bacterial meningitis, 
but retrospective studies have suggested a correlation between 
antibiotic delay and unfavorable patient outcomes.2–4 Therefore, 
the Infectious Diseases Society of America (IDSA) Practice 
Guidelines for the Management of Bacterial Meningitis indicate 
that patients with suspected bacterial meningitis should be 
treated as a “neurological emergency” and state that appropri-
ate therapy should be initiated as soon as possible after the 
diagnosis is considered likely.5
The IDSA guidelines recommend using dexamethasone in 
adults with suspected or proven pneumococcal meningitis, 
and in infants and children with Haemophilus influenzae type b 
meningitis. It is also recommended that the initial dose be 
administered just prior to or concomitantly with the first anti-
biotic dose, but that it not be used in patients who have already 
received an antibiotic, as it is unlikely to improve outcomes if 
given after antibiotics.2 
 The purpose of this study was to examine how frequently 
patients presenting with community-acquired bacterial menin-
gitis were administered guideline-recommended therapies of 
appropriate antibiotics and dexamethasone, and secondarily 
to examine the effects of early initiation of these therapies 
on patient outcomes of mortality and long-term neurological 
complications. 
METHODS
Following approval of the institutional review board, patients 
were identified by ICD-9 codes 320.1–320.99 for bacterial 
meningitis at two community teaching hospitals licensed for 
approximately 500 patient beds each. Both facilities share a 
level 1 trauma designation and have comprehensive emergency 
departments (EDs), with one having a children’s hospital. A 
retrospective review of electronic medical records and labora-
tory data was performed for all patients diagnosed from 2006 
to 2011. 
Patients were included, regardless of age, if they had a 
positive cerebrospinal fluid (CSF) culture or Gram’s stain or 
alternatively had three of the following findings in their CSF: 
a) a white blood cell count of more than 1,000 cells/mL; b) 
more than 80% neutrophils; c) elevated protein (more than 
Disclosure: The authors report no commercial or financial interests 
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100 mg/dL); d) decreased glucose (less than 40 mg/dL or 
CSF:serum glucose ratio less than 0.4) with at least one of the 
typical meningitis symptoms of nuchal rigidity, altered mental 
status, fever, or severe headache.
Patients were excluded if they had a potential nosocomial 
infection, defined as CSF culture obtained more than 48 hours 
after presentation, confirmed viral or fungal meningitis, CSF 
shunt, penetrating head trauma, history of neurosurgery, 
multiple admissions for bacterial meningitis (only the first 
episode was included), previously known neurological disorder, 
transfer from another hospital, cardiac or respiratory arrest 
upon arrival, or incomplete data.
Treatments were assessed for appropriate selection of anti-
biotics and use of dexamethasone. Appropriate antibiotics were 
defined as one of the recommended regimens for empiric treat-
ment based on the patient’s age according to IDSA practice 
guidelines (Table 1). Alternative therapies were deemed appro-
priate if the patient had a documented allergy that warranted 
use of an alternative antibiotic listed in the IDSA guidelines.5 
The time between presentation to the ED and administration 
of each antibiotic was evaluated, with a cut point of eight hours 
after arrival to the ED. Dexamethasone use was considered to 
be appropriate if administration of any dose occurred prior to or 
concomitantly with initial antibiotics. Mortality and neurological 
complications were assessed from discharge summaries and 
subsequent patient records when available, with a maximum 
follow-up of six years. Long-term neurological complications 
were defined as hearing loss, delayed development, or any 
neurological abnormalities documented as likely resulting from 
meningitis. Clinical outcomes of mortality and neurological 
complications were compared for groups of patients who did 
or did not receive timely guideline-recommended therapies. 
Patients who survived to discharge were analyzed for length 
of hospitalization.
Statistical analysis was performed with Excel 2010 (Microsoft, 
Redmond, Washington) and GraphPad QuickCalcs (GraphPad 
Software, Inc., La Jolla, California). Fisher’s exact test was used 
to compare mortality and neurological complications. Length 
of hospitalization was analyzed using the Student’s t-test for 
normally distributed data and Wilcoxon rank sum test for data 
not normally distributed. Two-sided alpha was set a priori at 
0.05 for all analyses.
RESULTS
A total of 161 diagnoses for bacterial meningitis occurred 
in the five years studied; 95 cases were at one institution and 
66 at the other. Thirty-eight patients met inclusion criteria, 19 
at each site. Demographic information of included patients 
is displayed in Table 2. A majority of excluded patients were 
excluded due to being transferred from outside facilities, pro-
hibiting analysis of initial pharmacological treatments. Table 3 
describes microbiology results of included patients.
Appropriate antibiotic selection and administration are dis-
played in Figure 1. Appropriate antibiotic administration, 
regardless of timing, occurred in 52.6% of patients. Omission of 
ampicillin was the most common deviation from the guidelines, 
occurring in 36.8% of patients, all more than 50 years of age. 
Other deviations from the guidelines included failure to receive 
a third-generation cephalosporin (10.5%) and failure to receive 
vancomycin (5.3%) when patients should have, according to 
IDSA guidelines. Two patients had more than one reason why 
antibiotic selection varied from guideline recommendations.
All patients received at least one recommended antibiotic. 
The median time between presentation to the ED and adminis-
tration of the first antibiotic was 4.2 hours; the second antibiotic 
was 7.0 hours (n = 32); and the entire guideline-recommended 
regimen, regardless of the number of needed antibiotics, 
was 8.6 hours (n = 20). Dexamethasone was used in 44.7% of 
patients, with 10.5% receiving a dose prior to the first antibiotic 
as recommended by the guidelines. 
Mortality rates according to appropriate antibiotic selec-
tion are displayed in Figure 2. No fatalities were observed 
among the patients who received a recommended antibiotic 
regimen within eight hours of arrival (n = 10). The median 
length of hospital stay was eight days (interquartile range 
[IQR], 6.3–12.8 days) for patients who received appropriate 
anti biotics within eight hours of arrival compared to 11 days 
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Table 2  Patient Demographics (n = 38)
Male 63.2%
Age, mean (range) 46.5 years (11 days–77 years)
< 1 month 18.4%
1 month–50 years 21.1%
≥ 50 years 60.5%
Table 1  Recommended Antibiotics Based on Patient Age5
Age Recommended Antibiotic Regimen
< 1 month Ampicillin + cefotaxime, OR ampicillin + 
aminoglycoside
1 month–50 years Vancomycin + third-generation cephalosporin*
> 50 years Vanocmycin + third-generation cephalosporin* 
+ ampicillin
* Cefotaxime or ceftriaxone.
Figure 1  Administration of Guideline-Recommended  
Antibiotics
> 8 hours
26%
< 8 hours
26%
Didn’t receive
48%
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(IQR, 5.0–16.8 days) for those who did not 
(P = 0.69). 
The use of dexamethasone and rate of neuro-
logical complications are displayed in Figure 3. 
No neurological complications were seen in the 
patients who received dexamethasone prior or con-
current to the first antibiotic (n = 4). Neurological 
complications were seen in two adults and three 
neonatal patients. One neonate was administered 
hydrocortisone one hour after antibiotics, while 
the other four patients did not receive cortico-
steroids at any time. The adults with neurological 
complications grew Streptococcus pneumoniae and 
group B Streptococcus, while the neonatal patients 
grew group B Streptococcus (two patients) and 
Escherichia coli. The most common neurologi-
cal complication was hearing loss (n = 4), with 
both delayed development and cerebral palsy later 
documented in one neonatal patient. 
DISCUSSION
While treatment guidelines for the manage-
ment of bacterial meningitis have been widely available since 
2004, new data have validated their recommendations. To our 
knowledge, this is the first study in the U.S. that assesses their 
adoption into practice.
Timing of antibiotics is an important discussion. Although no 
prospective studies exist regarding the relationship of antibiotic 
timing with clinical outcomes in bacterial meningitis, several 
retrospective studies have suggested a correlation between 
antibiotic timing and patient outcomes. A retrospective study 
of 305 patients showed that those who received an antibiotic 
prior to admission had a 1.9% mortality rate, compared to 12% 
in those with delayed treatment.2 A similar study of 171 cases 
of bacterial meningitis showed that patients who received 
antibiotics in the ED had a 10% mortality rate, compared to 
29% in patients who did not receive antibiotics in the ED.3 
Additionally, a multicenter retrospective study revealed that 
progression in disease severity before antibiotic administra-
tion was associated with significantly higher rates of adverse 
outcomes.4 These findings substantiate the importance of early 
antibiotic administration.
It is also relevant to discuss the analysis of time to antibiotics 
performed in this study. Practice guidelines from IDSA recom-
mend that antibiotics be initiated “as soon as possible after the 
diagnosis is considered to be likely.” Eight hours was chosen 
as the cutoff for time to administration based on several factors, 
including knowledge of the average duration of stay in our EDs 
and that many patients receive computed tomography studies 
prior to lumbar puncture. This time frame of eight hours has 
also been associated with improved outcomes in pneumonia 
patients and was familiar to prescribers due to previous use in 
Table 3  Cerebrospinal Fluid Culture Microbiology Results
Organism
Patient Age
Total< 1 month
1 month– 
50 years > 50 years
Streptococcus pneumoniae 1 11 12
Escherichia coli 2 2 4
Group B Streptococcus 2 1 3
Staphylococcus aureus 1 2 3
Coagulase-negative 
Staphylococcus 
1 1
Viridans group 
Streptococcus
1 1
Streptococcus bovis 1 1
Enterobacter species 1 1
No organism 1 5 6 12
Total 7 8 23 38
5.9%
19.0%
0%
5%
10%
15%
20%
5.0%
16.7%
5%
10%
15%
20%
Figure 2  Mortality Rate According 
To Antibiotic Administration
Figure 3  Long-Term Neurological Consequences  
According to Dexamethasone Administration
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quality measures.6 The authors feel that this time frame was a 
generous cutoff for a condition as serious as meningitis. While 
26.3% of patients had recommended antibiotics initiated within 
eight hours, changing the cut point to six hours or 12 hours 
would have resulted in 18.4% and 31.5% receiving recommended 
antibiotics, respectively, showing that, regardless of time point 
used, the findings are concerning. While the exact cause for 
the delay in treatment is not clear from available data, the fact 
that extending the cut point from eight hours to 12 hours had 
little effect on the number of patients meeting the measure 
suggests that it was unlikely to have been caused by delays 
in the preparation and delivery of antibiotics.
Another concerning finding was the low utilization of dexa-
methasone. There have been numerous studies of dexametha-
sone use in bacterial meningitis, several of which have shown 
a benefit. A prospective, placebo-controlled study showed that 
dexamethasone in adults with bacterial meningitis reduced 
unfavorable outcomes from 25% to 15% and mortality from 15% 
to 7%.7 In the subset of patients with pneumococcal disease, 
dexamethasone significantly reduced unfavorable outcomes 
from 52% to 26% and mortality from 34% to 14%.7 Based on 
these data, dexamethasone use for pneumococcal meningitis 
in the Netherlands increased from 3% in 1998–2002 to 84% in 
2006–2009, which showed a reduction in mortality from 30% 
to 20% and hearing loss from 22% to 12%, while unfavorable 
outcomes (Glasgow Coma Score less than 5 at discharge) 
decreased from 50% to 39%.8 More recently, long-term survival 
was confirmed to increase from 67% to 78% in patients receiving 
dexamethasone.9 Evidence also supports dexamethasone use 
in infants and children with meningitis caused by H. influen-
zae type b.10 Therefore, giving dexamethasone empirically is 
recommended for patients with suspected meningitis because 
it is not possible to safely determine the causative organism 
before administering antibiotics at the time of presentation.5 
In the present study, 12 adults grew S. pneumoniae, only two 
of whom (12.6%) received adjunctive dexamethasone prior to 
antibiotics. There were no confirmed cases of H. influenzae 
type b in infants and children, so dexamethasone use in this 
population may not have been beneficial.
Timely treatment for community-acquired bacterial menin-
gitis is important because early initiation of proper antibiotics 
has the potential to reduce mortality, and dexamethasone use 
has been proven to reduce neurological complications in select 
populations. Previous assessments of clinical practices have 
been reported by three European institutions, each having 
higher rates of adherence to guidelines than the current study, 
but all showing significant room for improvement.11–13 The 
overall mortality rate observed in this study, however, was 
slightly lower than what has been seen in previous studies. This 
may have been due to the high number of patients excluded 
because of transfer from other facilities.
In our study, patients who received antibiotics within 
eight hours of arrival had the numerically lowest mortality 
rate and shortest length of stay; however, the results did not 
reach statistical significance, likely due to the small sample 
size. Additionally, no long-term complications were observed 
in patients who received dexamethasone prior or concurrent 
to the first antibiotic dose.
Although results of this study did not reach statistical 
significance, they are consistent with larger trials and are 
meaningful because they may reflect current U.S. practice 
patterns that have been unpublished until now. Therefore, 
it is necessary to find ways to ensure stricter adherence 
to guideline recommendations in an attempt to decrease 
morbidity and mortality in these patients.
One solution to this problem of delayed antimicrobial therapy 
may be the implementation of standardized order sets for sus-
pected meningitis. Recognizing this, the studied institutions 
have cooperatively developed meningitis treatment protocols 
and have subsequently implemented them into computerized 
prescriber order-entry systems. Additionally, they are also 
working with outlying referral hospitals to improve processes 
at these facilities. Both of the medical centers involved in this 
study have assigned pharmacists to review orders and assist 
prescribers with treatment decisions in the ED, starting shortly 
after the end of our data.
The greatest limitations of this study are the small sample 
size and retrospective design. While trends in data are telling, 
small sample size may have contributed to II error, the failure to 
reject a false null hypothesis (a “false negative”). Even though 
161 cases of meningitis were treated at these medical centers 
during the time evaluated, a majority of patients could not be 
included in this study because they were transferred from 
other hospitals, which created incomplete data sets regard-
ing timing and administration of therapy. Additionally, many 
of the patients with ICD-9 codes for bacterial meningitis had 
been diagnosed based on clinical symptoms, but lab results 
did not meet study criteria. Inclusion of these patients would 
have created a larger sample size, but integrity of the data could 
have been compromised because some of these cases may not 
actually have been bacterial meningitis. The recognition of 
long-term neurological complications relied on documentation 
of such in the patients’ electronic medical records within the 
health system, but confirmation of specific testing could not 
be verified; therefore, this study may have underestimated 
the true prevalence. 
Although clear treatment recommendations for a variety 
of diseases exist, analyses have revealed adherence for many 
practice guidelines to be low.14 Careful ongoing review provides 
opportunities to identify and correct potential shortcomings at 
the point of prescribing. Our study has shown limited adherence 
to practice guidelines for bacterial meningitis and allowed us to 
make interventions in an attempt to ameliorate this problem. 
We are hopeful that implementing the new meningitis treat-
ment protocol across multiple medical facilities, integrating it 
into computerized prescriber order-entry systems, and making 
a clinical pharmacist available at the point of prescribing will 
improve adherence to guideline recommendations. Based on 
our results and previous literature, this has the potential to 
reduce mortality and prevent neurological sequelae in patients 
with meningitis.
CONCLUSION
Our data show that many patients presenting to EDs with 
community-acquired bacterial meningitis do not receive rec-
ommended antibiotics promptly after presentation or appropri-
ate administration of dexamethasone. These therapies have 
previously been shown to result in more favorable patient 
Selection and Timing of Therapy in Community-Acquired Bacterial Meningitis
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outcomes ranging from less hearing loss to lower mortal-
ity rates. Therefore, efforts must be made to improve the 
adherence with treatment guidelines for bacterial meningitis 
in hopes of improving patient outcomes.
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Therapy for Bacterial Meningitis CMS to Test Enhanced MTM Model
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lock-in programs and expanding access to state prescription 
drug monitoring program data to health plans.
Of course, at-risk beneficiaries are also the targets of the 
EMTM model, except that those being pinpointed will have 
costly medical conditions, such as diabetes and coronary heart 
disease. If Part D plans are able to better find and help those 
on the cusp or in the throes of opioid addiction—people often 
headed for bad outcomes—and also establish higher-value 
MTM programs, they will be on their way to a new era where 
“value” becomes a Part D watchword.
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